Your session is about to expire
← Back to Search
CC-220 Combination Therapy for Multiple Myeloma
Study Summary
This trial is testing a new drug, CC-220, for multiple myeloma, a cancer of the blood. The trial will test different doses of the drug, either alone or in combination with other drugs, to see what is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 289 Patients • NCT03161483Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with multiple myeloma and have not received any treatment.My multiple myeloma does not produce detectable levels of M protein.I do not have any health issues that would stop me from joining the study.I am not planned for or eligible for stem cell transplant as my initial treatment.My multiple myeloma has worsened within 2 months after my last treatment.I have been cancer-free for over 5 years, except for multiple myeloma or certain non-invasive cancers.I can take care of myself and am up and about more than half of my waking hours.
- Group 1: Cohort J2: CC-220 in combination with DEX and BTZ in NDMM - Part 2
- Group 2: Cohort B: CC-220 in combination with Dexamethasone (DEX) - Part 1
- Group 3: Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1
- Group 4: Cohort G1: CC-220 in combination with CFZ and DEX - Part 1
- Group 5: Cohort I: CC-220 in combination with DEX in post BCMA RRMM - Part 2
- Group 6: Cohort D: CC-220 in combination with Dexamethasone - Part 2
- Group 7: Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1
- Group 8: Cohort J1: CC-220 in combination with DEX and BTZ in NDMM - Part 2
- Group 9: Cohort C: CC-220 Monotherapy in RRMM - Part 2
- Group 10: Cohort K: CC-220 with DEX and DARA in NDMM and not autologous stem cell transplant eligible - Part 2
- Group 11: Cohort A: CC-220 Monotherapy - Part 1
- Group 12: Cohort F: CC-220 with DEX and bortezomib - Part 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are the focus of this research endeavor?
"Affirmative, the clinicaltrials.gov website reveals that this investigation is currently enlisting volunteers. The study was first announced on October 14th 2016 and saw its last update take place on November 27th 2022. 449 participants are needed for recruitment across 48 sites."
What afflictions is CC-220 most efficacious in addressing?
"CC-220 is a go-to intervention for ophthalmia, sympathetic and branch retinal vein occlusion. It has also proven to be effective in treating macular edema and communicable diseases."
Is there any availability for prospective participants to join this experiment?
"Affirmative. Online records on clinicaltrials.gov indicate that this medical trial, which was originally published on October 14th 2016, is actively enrolling patients. A total of 449 participants need to be recruited from 48 different locations."
What other explorations have been conducted with regards to CC-220?
"CC-220 was first studied in 2002 by the Manitoba Blood & Marrow Transplant Program CancerCare Manitoba. To date, 1487 trials have been completed with 689 more ongoing; particularly, many of these are located within Puyallup, Washington."
How many research centers are administering this study?
"Northwest Medical Specialties PLLC in Puyallup, Washington, Mount Sinai Brooklyn in Bonney Lake, New york, and Huntsman Cancer Institute at the University of Utah are amongst the many locations actively recruiting patients for this clinical trial."
Share this study with friends
Copy Link
Messenger